RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
RELMADA THERAPEUTICS, INC. (RLMD) had Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number of 110.00 thousand shares as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber · last filed 2024-11-07
- 2024-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 110.00K shares.
- 2024-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 1.81M shares.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 2.38M shares.
- 2023-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 3.03M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number as first filed |
|---|---|---|
| 2024-09-30 | 110.00K shares 10-Q · filed 2024-11-07 | |
| 2024-06-30 | 1.81M shares 10-Q · filed 2024-08-07 | |
| 2023-12-31 | 2.38M shares 10-Q · filed 2024-08-07 | |
| 2023-09-30 | 3.03M shares 10-Q · filed 2023-11-08 | |
| 2022-12-31 | 3.03M shares 10-Q · filed 2023-11-08 | |
| 2022-03-31 | 3.18M shares 10-Q · filed 2022-05-05 | |
| 2021-12-31 | 3.21M shares 10-K · filed 2023-03-23 | |
| 2021-12-30 | 2.76M shares 10-Q · filed 2021-08-10 | |
| 2021-09-30 | 3.24M shares 10-Q · filed 2021-11-12 | |
| 2021-06-30 | 2.67M shares 10-Q · filed 2021-08-10 | |
| 2021-03-31 | 2.80M shares 10-Q · filed 2021-05-12 | |
| 2020-12-31 | 2.67M shares 10-K · filed 2023-03-23 | |
| 2019-12-31 | 3.65M shares 10-K · filed 2022-03-25 | 3.65M shares 10-K · filed 2021-03-24 |
| 2019-06-30 | 4.43M shares 10-K · filed 2021-03-24 | |
| 2018-06-30 | 2.45M shares 10-K · filed 2021-03-24 | |
| 2013-12-31 | 8.93M shares 10-K · filed 2015-09-11 | |
| 2012-12-31 | 4.87M shares 10-K · filed 2015-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |